Sanofi Contingent Value Rights
GCVRZ
GCVRZ was delisted on the 3rd of March, 2020.
106 hedge funds and large institutions have $13.5M invested in Sanofi Contingent Value Rights in 2016 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 14 increasing their positions, 18 reducing their positions, and 16 closing their positions.
7% more capital invested
Capital invested by funds: $12.6M → $13.5M (+$914K)
7% less funds holding
Funds holding: 114 → 106 (-8)
22% less repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 18
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
50% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 16
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Stonehill Capital Management
New York
|
+$581K |
| 2 |
MFP
Michael F. Price
|
+$205K |
| 3 |
CL
CSS LLC
Chicago,
Illinois
|
+$84K |
| 4 |
TL
TowerView LLC
New York
|
+$32.3K |
| 5 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$27K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SAM
Silverback Asset Management
Chapel Hill,
North Carolina
|
-$97K |
| 2 |
ACM
Akanthos Capital Management
Woodland Hills,
California
|
-$75K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$31K |
| 4 |
PC
Permanens Capital
New York
|
-$13K |
| 5 |
ZIG
Zuckerman Investment Group
Chicago,
Illinois
|
-$6.16K |
GCVRZ Hedge Fund Activity: Q1 2016 in Review
106 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in Sanofi Contingent Value Rights (GCVRZ) for Q1 2016, worth a combined $13.5M — up 7.2% from $12.6M a quarter earlier.
Sellers outnumbered buyers: 16 funds closed out of GCVRZ and 8 opened new positions — a net loss of 8 holders — while 18 trimmed existing stakes and 14 added.
The largest buyer was Stonehill Capital Management, adding an estimated $581K. The largest seller was Silverback Asset Management, exiting entirely with an estimated $97K sold.
- 106 institutional investors held Sanofi Contingent Value Rights (GCVRZ) as of Q1 2016, down from 114 in Q4 2015.
- Funds reported $13.5M of Sanofi Contingent Value Rights stock for Q1 2016, up 7.2% quarter-over-quarter.
- 8 funds opened new Sanofi Contingent Value Rights positions in Q1 2016 and 16 closed out, a net change of -8 holders.
- The largest Sanofi Contingent Value Rights buyer in Q1 2016 was Stonehill Capital Management, an estimated $581K added.
- The largest Sanofi Contingent Value Rights seller in Q1 2016 was Silverback Asset Management, an estimated $97K sold.
Based on aggregated 13F filings for Q1 2016.